An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Broker Canaccord Genuity says this ASX share potentially 'has no value from here'. Here's what is happening with this ...

The company said this morning that the COAST trial of sozinibercept (OPT-302) as a combination therapy with blockbuster wet AMD therapy Regeneron/Bayer's Eylea (aflibercept) wasn't able to show ...

Opthea raised $113 million in an institutional share placement that will be used to fund further phase 3 development of sozinibercept (OPT-302), a treatment for vision-robbing disease wet age ...

- ETFs amassed $296 billion in the first quarter of 2025, setting a new record. - European ETFs saw second-highest inflows ever amid tariff concerns. - Inflation-sensitive assets like gold drew ...